Entry-modulating agents and uses therefor
OwnerMichael P. Jennings, Christopher J. Day +1inventors
InventorsMichael P. Jennings, Christopher J. Day, Gerd Pluschke
Life of this patent
Estimating the term…
Abstract
This disclosure relates generally to the use of compounds that inhibit binding of Plasmodium cysteine-rich protective antigen (CyRPA) to glycans of cells that are susceptible to infection by Plasmodium pathogens, including glycans terminating with α2-6-linked sialic acid, in methods, compositions and kits for inhibiting the interaction of a Plasmodium pathogen to Plasmodium-binding glycan-expressing cells, including α2-6-linked sialic acid-expressing cells such as erythrocytes, and for treating or inhibiting the development of malaria.
Claims20
A method for inhibiting interaction of a Plasmodium cysteine-rich protective antigen (CyRPA) with a cell that is capable of being infected by a Plasmodium pathogen, the method comprising, consisting or consisting essentially of contacting the CyRPA with a ligand of the CyRPA which when bound to the CyRPA inhibits interaction of the CyRPA with the cell.
A method for treating or inhibiting the development of a Plasmodium pathogen infection in a subject, the method comprising, consisting or consisting essentially of administering to the subject an effective amount of a ligand of a cysteine-rich protective antigen (CyRPA) expressed by the Plasmodium pathogen which ligand, when bound to the CyRPA, inhibits interaction of the CyRPA with a cell that is capable of being infected by the Plasmodium pathogen, to thereby treat or inhibit the development of the Plasmodium pathogen infection in the subject.
A composition for use in therapy or prophylaxis of a Plasmodium pathogen infection in a subject, the composition comprising, consisting or consisting essentially of a ligand of a P. falciparum CyRPA which, when bound to the CyRPA, inhibits interaction of the CyRPA with an α2-6-linked sialic acid of an α2-6-linked sialic acid-expressing cell, and optionally a pharmaceutically acceptable carrier.
A kit for use in treating a Plasmodium pathogen infection in a subject, the kit comprising:
- a ligand of a Plasmodium pathogen CyRPA which, when bound to the CyRPA, inhibits interaction of the CyRPA with an α2-6-linked sialic acid of an α2-6-linked sialic acid-expressing cell, and optionally instructional material for performing the treatment.
A method for treating or inhibiting the development of a Plasmodium pathogen infection in a subject the method comprising, consisting or consisting essentially of administering to the subject an effective amount of a compound of formula (I):
- to thereby treat or inhibit the development of the Plasmodium pathogen infection in the subject.
A method for treating a Plasmodium pathogen infection in a subject the method comprising, consisting or consisting essentially of administering to the subject an effective amount of a compound of formula (II):
A method for treating or inhibiting the development of a Plasmodium pathogen infection in a subject the method comprising, consisting or consisting essentially of administering to the subject an effective amount of a compound of formula (III):
Dependencies are inferred from the claim text.